Pharma R&D SEZ – The Catalyst for India’s Next-Gen Pharmaceutical Innovations

Advancing Healthcare, Accelerating Breakthroughs, and Transforming Global Pharma

Pharma R&D SEZ

The Pharma R&D SEZ at Quantum Semicon Smart City is India’s premier biopharmaceutical research and drug development hub, modeled on Switzerland’s Basel Pharma Hub, South Korea’s Osong Bio Valley, and the US’s Boston Biotech Corridor. This SEZ will drive drug discovery, biosimilars, precision medicine, vaccine development, and AI-powered pharmaceutical innovation, reducing India’s reliance on imported high-value medicines and patented technologies.

By integrating cutting-edge R&D labs, clinical trial facilities, biopharmaceutical manufacturing zones, and advanced AI-driven drug discovery hubs, this SEZ will position India as a global leader in pharmaceutical exports and life sciences innovation.

Vision

To establish India as a global powerhouse in pharmaceutical research and drug development, leading breakthroughs in personalized medicine, biosimilars, AI-powered drug discovery, and life-saving vaccines.

Mission

Develop state-of-the-art pharma R&D infrastructure, enabling cutting-edge innovation in drug discovery, formulation science, and biotechnology.
Attract leading global pharma companies like Pfizer, Moderna, Novartis, Roche, and Biocon to establish research and manufacturing centers.
Foster India’s self-reliance in critical drugs and vaccines, reducing import dependency.
Build a world-class ecosystem for biotech startups, clinical trials, and AI-driven pharmaceutical analytics.
Position India as a top exporter of biosimilars, generics, biologics, and advanced pharmaceutical therapies.

Strategic Importance of the Pharma R&D SEZ

Strengthening India’s Position as a Global Pharma Innovation Hub

India is the world’s largest supplier of generic medicines, but it imports nearly 70% of its active pharmaceutical ingredients (APIs) and high-value biologics. The Pharma R&D SEZ will bridge this gap by enabling domestic production of high-value drugs, ensuring India becomes a leader in global pharmaceutical exports.

By 2028, India aims to be the top global supplier of biosimilars, precision medicine solutions, and AI-powered pharmaceutical innovations.

World-Class Pharmaceutical R&D Infrastructure

A High-Tech Ecosystem for Biopharma, Clinical Trials & AI Drug Discovery

The Pharma R&D SEZ will feature:

Biopharmaceutical Research & Development Centers, accelerating biosimilars, monoclonal antibodies, and regenerative medicine innovations.
AI-Powered Drug Discovery Hubs, integrating machine learning models for faster, cost-effective drug development.
GMP-Compliant Manufacturing Zones, ensuring high-quality drug formulation and clinical-grade biologics production.
Vaccine Development & Testing Labs, enabling rapid vaccine production and infectious disease research.
Clinical Trial & Regulatory Testing Facilities, supporting India’s role as a global hub for pharmaceutical testing and approvals.

By developing world-class pharmaceutical R&D infrastructure, this SEZ will drive India’s leadership in life sciences and biopharmaceutical exports.

Attracting Global Pharma & Biotech Leaders

A Global Investment Hub for Life Sciences & Drug Innovation

The Pharma R&D SEZ will provide fast-track drug approvals, tax-free R&D incentives, and patent commercialization support, attracting global pharma leaders, including:

Pfizer, Moderna, and AstraZeneca – Next-gen vaccine development and mRNA technology innovation.
Novartis, Roche, and Sanofi – AI-powered drug discovery, biosimilars, and oncology research.
Gilead Sciences, Biocon, and Amgen – Biologics, regenerative medicine, and monoclonal antibody therapy breakthroughs.
Takeda Pharmaceuticals, Johnson & Johnson, and Merck – Rare disease drug development and precision medicine.

By fostering industry-academia collaborations and AI-driven pharmaceutical startups, this SEZ will accelerate India’s emergence as a global pharma innovation hub.

Self-Reliance & Export Excellence in Biopharma & Drug Development

Reducing Pharma Imports & Strengthening India’s Global Drug Supply Chain

India imports over $25 billion in APIs, biologics, and patented drugs annually. The Pharma R&D SEZ will reverse this trend by:

Developing India’s own high-value pharmaceutical supply chain, reducing dependency on imports.
Strengthening India’s position as a trusted supplier of vaccines, biosimilars, and personalized medicine solutions.
Driving India’s emergence as a leading exporter of next-gen pharmaceuticals to Europe, North America, and Asia.

By 2035, India aims to be the top global supplier of biosimilars, AI-powered drug discovery solutions, and next-gen medicine, with over $100 billion in annual pharmaceutical exports.

Breakthroughs in AI-Powered Drug Discovery & Precision Medicine

Revolutionizing Healthcare with Data-Driven Pharma Innovation

The Pharma R&D SEZ will accelerate cutting-edge research in:

AI-Powered Drug Development, reducing the time and cost of drug discovery by up to 70%.
Genomics & Personalized Medicine, enabling customized treatments based on genetic profiling.
mRNA & CRISPR-Based Therapeutics, advancing gene editing for rare diseases and cancer treatment.
AI-Driven Clinical Trial Optimization, reducing costs and improving efficiency in new drug approvals.

By integrating AI-driven research, biotech advancements, and pharmaceutical innovation, this SEZ will redefine India’s leadership in life sciences.

Job Creation & Talent Development

Building India’s Future Workforce in Biopharma & AI-Driven Drug Research

The Pharma R&D SEZ will create over 120,000 direct and indirect jobs, fostering expertise in:

Drug formulation, biosimilar production, and monoclonal antibody research.
AI-powered predictive drug discovery, bioinformatics, and medical data analytics.
Regenerative medicine, gene therapy, and next-gen vaccine development.
Clinical trial management, pharmaceutical policy, and regulatory compliance.

Through partnerships with IITs, AIIMS, Biocon Academy, and global biotech universities, this SEZ will ensure India’s workforce is prepared for the next revolution in pharmaceuticals.

Sustainability & Green Biopharma Manufacturing

Eco-Friendly Drug Production, AI-Optimized Research, and Zero-Waste Pharma Solutions

Pharmaceutical R&D and drug production require sustainable processes. The Pharma R&D SEZ will champion:

AI-Driven Green Pharma Research, ensuring low-impact drug production methods.
Zero-Waste Biomanufacturing, enabling closed-loop, environmentally friendly drug formulation.
Sustainable API & Biosimilar Production, reducing carbon emissions and chemical waste.

By integrating eco-friendly biopharma practices, this SEZ will ensure India remains a leader in sustainable pharmaceutical development.

Why Invest in the Pharma R&D SEZ?

Strategic Location: Positioned near leading medical research institutes, biotech clusters, and global pharma trade routes.
World-Class Infrastructure: GMP-compliant biopharma labs, AI-driven drug research hubs, and vaccine production centers.
Government Incentives: PLI schemes, tax-free R&D grants, and fast-track clinical trial approvals.
Highly Skilled Workforce: Access to India’s top biotech researchers, AI specialists, and pharmaceutical scientists.
Global Market Reach: Positioned as a leading exporter of next-gen pharmaceuticals and biosimilars.

Be Part of India’s Pharma Revolution

Shape the Future of Life Sciences at the Pharma R&D SEZ

The Pharma R&D SEZ at Quantum Semicon Smart City is India’s premier pharmaceutical innovation hub. Whether you’re a global pharma company, biotech startup, or AI-driven drug discovery firm, this SEZ offers state-of-the-art facilities, strong government backing, and a thriving biotech ecosystem.

Contact us today to explore investment opportunities and drive the future of pharmaceutical innovation in India!

Tailored Solutions for Modern Urban Challenges

Strategic Importance of the Integrated Circuits SEZ

Strengthening India’s Semiconductor Industry for Domestic & Global Markets
The Integrated Circuits SEZ will not only catalyze India's digital economy but also create a sustainable and globally competitive semiconductor industry. With a focus on both export-led growth and domestic supply security, this SEZ will integrate India into global semiconductor supply chains while ensuring that the country has access to critical technologies required for industrial and consumer applications.